Roche to transfer technology for Saquinavir to three generic drug companies in Africa

Switzerland-based pharmaceutical company Roche on Friday said it will provide three generic drug companies in sub-Saharan Africa assistance in producing the protease inhibitor saquinavir under its Technology Transfer Initiative, Reuters South Africa reports (Reuters South Africa, 9/22).

The technology transfer for saquinavir -- which is recommended by the World Health Organization as a second-line HIV/AIDS treatment in resource-poor countries -- is available to drug makers in 63 developing nations.

About 69% of HIV-positive people worldwide live in countries covered under Roche's TTI (Kaiser Daily HIV/AIDS Report, 1/13).

Roche will transfer the technology to South Africa-based Aspen Pharmacare and Kenya-based Cosmos and Universal Corp., Dow Jones/Easy Bourse reports.

"We welcome the commitment from these companies to produce their own quality generic versions of saquinavir," Lembit Raego, coordinator of quality assurance and safety of medicines at the WHO, said, adding, "The technical assistance from Roche should help strengthen and extend their manufacturing abilities for quality medicines" (Dow Jones/Easy Bourse, 9/22).

Another 25 companies have expressed interest in the TTI, AFX/Forbes reports (AFX/Forbes, 9/22).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists unveil a 3D photoacoustic scanner that speeds up vascular imaging for real-time clinical use